These findings suggest that inhibiting or blocking the plasminogen/uPA pathways with a specific antibody (Ab) or inhibitor may interfere with the generation of plasmin, resulting in decreased pericellular proteolytic activity and tumor metastasis. Here, PLG is linked to neoplasm.